Disc Medicine (IRON) Depreciation & Amortization (CF) (2020 - 2026)
Disc Medicine (IRON) reported Depreciation & Amortization (CF) of $89000.0 for Q1 2026, up 345.0% year-over-year from $20000.0 in Q1 2025, and little changed on a QoQ basis from $89000.0 in Q4 2025.
Disc Medicine (IRON) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $89000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 345.0% year-over-year to $89000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $350000.0 (up 133.33% YoY) and the FY2025 annual result came in at $281000.0, up 80.13% from the prior year.
- Depreciation & Amortization (CF) held at $89000.0 in Q1 2026 per IRON's latest filing, from $89000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $110000.0 in Q2 2024 and bottomed at $9000.0 in Q4 2024.
- The 5-year median for Depreciation & Amortization (CF) is $25000.0 (2022), against an average of $42058.8.
- The widest annual swing landed in 2022, when Depreciation & Amortization (CF) slumped 72.31%; it then surged 888.89% in 2025.
- Tracing IRON's Depreciation & Amortization (CF) over 5 years: stood at $25000.0 in 2022, then changed by 0.0% to $25000.0 in 2023, then slumped by 64.0% to $9000.0 in 2024, then surged by 888.89% to $89000.0 in 2025, then changed by 0.0% to $89000.0 in 2026.
- Per Business Quant, the three latest IRON Depreciation & Amortization (CF) figures stand at $89000.0 (Q1 2026), $89000.0 (Q4 2025), and $87000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | 89,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89,000.00 |
| Mar 31, 2026 | 89,000.00 |
| Dec 31, 2025 | 89,000.00 |
| Dec 31, 2025 | 89,000.00 |
| Sep 30, 2025 | 87,000.00 |
| Sep 30, 2025 | 87,000.00 |
| Jun 30, 2025 | 85,000.00 |
| Jun 30, 2025 | 85,000.00 |
| Mar 31, 2025 | 20,000.00 |
| Mar 31, 2025 | 20,000.00 |
| Dec 31, 2024 | 9,000.00 |
| Dec 31, 2024 | 9,000.00 |
| Sep 30, 2024 | 11,000.00 |
| Sep 30, 2024 | 11,000.00 |
| Jun 30, 2024 | 110,000.00 |
| Jun 30, 2024 | 110,000.00 |
| Mar 31, 2024 | 26,000.00 |
| Mar 31, 2024 | 26,000.00 |
| Dec 31, 2023 | 25,000.00 |
| Dec 31, 2023 | 25,000.00 |
| Sep 30, 2023 | 25,000.00 |
| Sep 30, 2023 | 25,000.00 |
| Jun 30, 2023 | 25,000.00 |
| Jun 30, 2023 | 25,000.00 |
| Mar 31, 2023 | 25,000.00 |
| Mar 31, 2023 | 25,000.00 |
| Dec 31, 2022 | 25,000.00 |
| Dec 31, 2022 | 25,000.00 |
| Sep 30, 2022 | 24,000.00 |
| Sep 30, 2022 | 24,000.00 |
| Jun 30, 2022 | 22,000.00 |
| Jun 30, 2022 | 22,000.00 |
| Mar 31, 2022 | 18,000.00 |
| Mar 31, 2022 | 18,000.00 |
| Dec 31, 2021 | 46,000.00 |
| Dec 31, 2021 | 46,000.00 |
| Sep 30, 2021 | 58,000.00 |
| Sep 30, 2021 | 58,000.00 |
| Jun 30, 2021 | 62,000.00 |
| Jun 30, 2021 | 62,000.00 |
| Mar 31, 2021 | 65,000.00 |
| Mar 31, 2021 | 65,000.00 |
| Dec 31, 2020 | 87,000.00 |
| Dec 31, 2020 | 87,000.00 |
| Sep 30, 2020 | 80,000.00 |
| Sep 30, 2020 | 80,000.00 |
| Jun 30, 2020 | 78,000.00 |
| Jun 30, 2020 | 78,000.00 |
| Mar 31, 2020 | 77,000.00 |
| Mar 31, 2020 | 77,000.00 |